- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00340275
Longitudinal Study of Vaginal Flora
30 de junio de 2017 actualizado por: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Bacterial vaginosis is a syndrome manifested by adverse alterations in vaginal microbial flora.
It is present in 10 to 25% of women in the general population, and is the most common vaginal infection.
It has been associated with a number of adverse sequelae in reproductive health including acquisition of HIV, pelvic inflammatory disease, cervical dysplasia, and complications of gynecological procedures.
During pregnancy it has been associated with an increased risk of preterm birth an postpartum maternal infection.
However, the vaginal microbial flora remains poorly understood.
Information on variation in microbial flora and its association with BV from a longitudinal study is unavailable.
This prospective observational study aims to advance our knowledge of the natural history and abnormal alteration in vaginal microbial flora, and to identify risk factors that are associated with these changes.
A total of 5500 healthy, non-pregnant women of reproductive age will be enrolled and followed up in Birmingham, Alabama, for one year (baseline visit plus once every three months afterwards, totaling 5 visits).
Detailed information on sociodemographic status, medical history, hygiene practice, sexual behavior and psychosocial stress will be collected through in-person interviews.
Routine gynecological and dental examinations will be carried out during the study visits.
Samples of vaginal secretion and blood will be collected.
Laboratory tests to quantify vaginal microbial flora and to identify infection of bacterial vaginosis as well as common sexually transmitted diseases will be conducted.
This project is expected to complete in 5 years.
Descripción general del estudio
Estado
Terminado
Condiciones
Descripción detallada
Bacterial vaginosis is a syndrome manifested by adverse alterations in vaginal microbial flora.
It is present in 10 to 25% of women in the general population, and is the most common vaginal infection.
It has been associated with a number of adverse sequelae in reproductive health including acquisition of HIV, pelvic inflammatory disease, cervical dysplasia, and complications of gynecological procedures.
During pregnancy it has been associated with an increased risk of preterm birth and postpartum maternal infection.
However, the vaginal microbial flora remains poorly understood.
Information on variation in microbial flora and its association with BV from a longitudinal study is unavailable.
This prospective observational study aims to advance our knowledge of the natural history and abnormal alteration in vaginal microbial flora, and to identify risk factors that are associated with these changes.
A total of 5500 healthy, non-pregnant women of reproductive age will be enrolled and followed up in Birmingham, Alabama, for one year (baseline visit plus once every three months afterwards, totaling 5 visits).
Detailed information on sociodemographic status, medical history, hygiene practice, sexual behavior and psychosocial stress will be collected through in-person interviews.
Routine gynecological and dental examinations will be carried out during the study visits.
Samples of vaginal secretion and blood will be collected.
Laboratory tests to quantify vaginal microbial flora and to identify infection of bacterial vaginosis as well as common sexually transmitted diseases will be conducted.
This project is expected to complete in 5 years.
Tipo de estudio
De observación
Inscripción (Anticipado)
5500
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos
- University of Alabama
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
15 años a 44 años (Niño, Adulto)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Femenino
Descripción
- ELIGIBILITY CRITERIA:
- Females, age 15-44.
- Since bacterial vaginosis is primarily a condition of reproductive-age women, this study will be restricted to women regarded by demographers as reproductive age.
- Non-pregnant women whose last menstrual period is later than expected will undergo a urine pregnancy test. Women who become pregnant while on study will complete their next regularly scheduled study visit, following which their participation will terminate.
EXCLUSION CRITERIA:
Immunocompromised status
Receiving or expected to receive in the next 12 months cytotoxic or immunosuppressive drugs.
Receiving or expected to receive in the next 12 months one or more 30-day courses of corticosteroids.
Congenital or acquired immune deficiency; known HIV positivity.
- Primary or secondary affective disorder, psychosis, emotional or intellectual limitations that preclude informed consent.
- Non-fluency in English.
- Post-menopausal (natural or surgical).
- Status post hysterectomy or expected to undergo hysterectomy in the next 12 months.
- Status post pelvic radiotherapy, or expected to undergo pelvic radiotherapy in the next 12 months.
- Receiving or expected to receive chronic (daily for at least 30 days) antibiotics in the next 12 months.
- Planning to move out of the area in the next 12 months.
- Participating or expected to participate during the next 12 months in a clinical trial in which antibiotics or topical microbicides will be administered in a blinded manner.
- Women who unexpectedly develop one of these conditions during their participation will continue to be followed, unless a specific contraindication arises.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Publicaciones Generales
- Goldenberg RL, Klebanoff MA, Nugent R, Krohn MA, Hillier S, Andrews WW. Bacterial colonization of the vagina during pregnancy in four ethnic groups. Vaginal Infections and Prematurity Study Group. Am J Obstet Gynecol. 1996 May;174(5):1618-21. doi: 10.1016/s0002-9378(96)70617-8.
- Fanchin R, Harmas A, Benaoudia F, Lundkvist U, Olivennes F, Frydman R. Microbial flora of the cervix assessed at the time of embryo transfer adversely affects in vitro fertilization outcome. Fertil Steril. 1998 Nov;70(5):866-70. doi: 10.1016/s0015-0282(98)00277-5.
- Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983 Jan;74(1):14-22. doi: 10.1016/0002-9343(83)91112-9.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
14 de abril de 1999
Finalización del estudio
18 de noviembre de 2010
Fechas de registro del estudio
Enviado por primera vez
19 de junio de 2006
Primero enviado que cumplió con los criterios de control de calidad
19 de junio de 2006
Publicado por primera vez (Estimar)
21 de junio de 2006
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
2 de julio de 2017
Última actualización enviada que cumplió con los criterios de control de calidad
30 de junio de 2017
Última verificación
18 de noviembre de 2010
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- 999999023
- OH99-CH-N023
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .